|
• |
该公司收到了更正后的FDA关于维罗布利单抗治疗化脓性汗腺炎第三阶段试验的建议函
|
• |
在坏疽脓皮病中使用维罗布利单抗报告的IIa期阳性数据;数据在AAD年会上以晚期口头报告的形式公布
|
• |
预计3月底前在重症新冠肺炎的VILOBLIMAB III期试验中的背线数据
|
• |
美国和欧盟在AAV中使用viloblimab进行的第二阶段试验都达到了他们的目标
|
• |
在CSCC登记中使用viloblimab的第二阶段试验,预计今年晚些时候会有第一次疗效数据
|
• |
最近推出的新程序INF904口服C5aR小分子抑制剂
|
• |
年终现金和现金等价物约2620万欧元,金融资产约8440万欧元
|
|
|
|
|
|
|
欧元,股票信息除外
|
2021
|
2020
|
2019
|
|||||||||
运营费用
|
||||||||||||
研发费用
|
(35,697,935
|
)
|
(25,684,140
|
)
|
(44,582,136
|
)
|
||||||
一般和行政费用
|
(11,984,722
|
)
|
(8,467,203
|
)
|
(12,501,048
|
)
|
||||||
总运营费用
|
(47,682,657
|
)
|
(34,151,343
|
)
|
(57,083,184
|
)
|
||||||
其他收入
|
54,221
|
221,748
|
400,253
|
|||||||||
其他费用
|
(6,381
|
)
|
(13,209
|
)
|
(85,242
|
)
|
||||||
运营结果
|
(47,634,816
|
)
|
(33,942,804
|
)
|
(56,768,173
|
)
|
||||||
财政收入
|
109,391
|
887,702
|
2,840,676
|
|||||||||
财务费用
|
(24,769
|
)
|
(26,000
|
)
|
(22,265
|
)
|
||||||
换汇结果
|
1,964,135
|
(776,512
|
)
|
694,944
|
||||||||
其他财务结果
|
(44,000
|
)
|
(126,000
|
)
|
—
|
|||||||
所得税
|
—
|
—
|
—
|
|||||||||
当期亏损
|
(45,630,059
|
)
|
(33,983,614
|
)
|
(53,254,817
|
)
|
||||||
共享信息
|
||||||||||||
加权平均流通股数
|
41,629,974
|
27,064,902
|
26,004,519
|
|||||||||
每股亏损(基本/稀释后)
|
(1.10
|
)
|
(1.26
|
)
|
(2.05
|
)
|
||||||
当期亏损
|
(45,630,059
|
)
|
(33,983,614
|
)
|
(53,254,817
|
)
|
||||||
可在以后期间重新分类为损益的其他全面收益(亏损):
|
||||||||||||
外币兑换中的汇兑差额
|
6,777,061
|
(5,954,019
|
)
|
2,177,033
|
||||||||
全面亏损总额
|
(38,852,998
|
)
|
(39,937,633
|
)
|
(51,077,785
|
)
|
|
in €
|
2021
|
2020
|
||||||
资产
|
||||||||
非流动资产
|
||||||||
财产和设备*
|
274,373
|
408,263
|
||||||
使用权资产*
|
1,408,078
|
546,694
|
||||||
无形资产
|
235,216
|
350,183
|
||||||
其他资产
|
336,566
|
353,522
|
||||||
金融资产
|
27,206,990
|
272,268
|
||||||
非流动资产总额
|
29,461,224
|
1,930,930
|
||||||
流动资产
|
||||||||
流动其他资产*
|
10,983,458
|
3,734,700
|
||||||
应收所得税*
|
1,282,177
|
1,419,490
|
||||||
金融资产
|
57,162,266
|
55,162,033
|
||||||
现金和现金等价物
|
26,249,995
|
25,968,681
|
||||||
流动资产总额
|
95,677,896
|
86,284,904
|
||||||
总资产
|
125,139,120
|
88,215,834
|
||||||
权益和负债
|
||||||||
权益
|
||||||||
已发行资本
|
5,304,452
|
3,387,410
|
||||||
股票溢价
|
280,310,744
|
220,289,876
|
||||||
其他资本储备
|
30,591,209
|
26,259,004
|
||||||
累计赤字
|
(213,975,679
|
)
|
(168,345,620
|
)
|
||||
股本的其他组成部分
|
3,050,270
|
(3,726,791
|
)
|
|||||
总股本
|
105,280,996
|
77,863,880
|
||||||
非流动负债
|
||||||||
租赁负债
|
1,066,354
|
220,525
|
||||||
其他负债
|
35,019
|
33,323
|
||||||
非流动负债总额
|
1,101,373
|
253,847
|
||||||
流动负债
|
||||||||
贸易和其他应付款
|
8,574,244
|
8,258,133
|
||||||
收到的政府赠款的负债
|
8,300,000
|
—
|
||||||
租赁负债
|
366,171
|
338,516
|
||||||
雇员福利
|
1,378,130
|
1,368,731
|
||||||
其他负债
|
138,206
|
117,727
|
||||||
条文
|
—
|
15,000
|
||||||
流动负债总额
|
18,756,751
|
10,098,107
|
||||||
总负债
|
19,858,124
|
10,351,954
|
||||||
权益和负债总额
|
125,139,120
|
88,215,834
|
|
in €
|
已发布
资本
|
分享
补价
|
其他
资本储备
|
累计赤字
|
其他
股本的组成部分
|
总计
股权
|
||||||||||||||||||
截至2019年1月1日的余额
|
3,115,725
|
211,021,835
|
18,310,003
|
(81,107,188
|
)
|
50,196
|
151,390,571
|
|||||||||||||||||
当期亏损
|
—
|
—
|
—
|
(53,254,817
|
)
|
—
|
(53,254,817
|
)
|
||||||||||||||||
汇兑差额
外币的兑换
|
—
|
—
|
—
|
—
|
2,177,033
|
2,177,033
|
||||||||||||||||||
全面亏损总额
|
—
|
—
|
—
|
(53,254,817
|
)
|
2,177,033
|
(51,077,784
|
)
|
||||||||||||||||
以股权结算的股份薪酬
|
—
|
—
|
6,832,210
|
—
|
—
|
6,832,210
|
||||||||||||||||||
已行使的购股权
|
16,905
|
(15,229
|
)
|
—
|
—
|
—
|
1,676
|
|||||||||||||||||
截至2019年12月31日的余额
|
3,132,631
|
211,006,606
|
25,142,213
|
(134,362,006
|
)
|
2,227,228
|
107,146,673
|
|||||||||||||||||
当期亏损
|
—
|
—
|
—
|
(33,983,614
|
)
|
—
|
(33,983,614
|
)
|
||||||||||||||||
汇兑差额
外币的兑换
|
—
|
—
|
—
|
—
|
(5,954,019
|
)
|
(5,954,019
|
)
|
||||||||||||||||
全面亏损总额
|
—
|
—
|
—
|
(33,983,614
|
)
|
(5,954,019
|
)
|
(39,937,633
|
)
|
|||||||||||||||
发行普通股
|
234,982
|
9,535,961
|
—
|
—
|
—
|
9,770,943
|
||||||||||||||||||
交易成本
|
—
|
(729,840
|
)
|
—
|
—
|
—
|
(729,840
|
)
|
||||||||||||||||
以股权结算的股份薪酬
|
—
|
—
|
1,116,791
|
—
|
—
|
1,116,791
|
||||||||||||||||||
已行使的购股权
|
19,797
|
477,149
|
—
|
—
|
—
|
496,946
|
||||||||||||||||||
2020年12月31日的余额
|
3,387,410
|
220,289,876
|
26,259,004
|
(168,345,620
|
)
|
(3,726,791
|
)
|
77,863,880
|
||||||||||||||||
当期亏损
|
—
|
—
|
—
|
(45,630,059
|
)
|
—
|
(45,630,059
|
)
|
||||||||||||||||
汇兑差额
外币的兑换
|
—
|
—
|
—
|
—
|
6,777,061
|
6,777,061
|
||||||||||||||||||
全面亏损总额
|
—
|
—
|
—
|
(45,630,059
|
)
|
6,777,061
|
(38,852,998
|
)
|
||||||||||||||||
发行普通股
|
1,873,203
|
63,269,346
|
—
|
—
|
—
|
65,142,549
|
||||||||||||||||||
交易成本
|
—
|
(4,219,222
|
)
|
—
|
—
|
—
|
(4,219,222
|
)
|
||||||||||||||||
以股权结算的股份薪酬
|
—
|
—
|
4,332,205
|
—
|
—
|
4,332,205
|
||||||||||||||||||
已行使的购股权
|
43,839
|
970,744
|
—
|
—
|
—
|
1,014,583
|
||||||||||||||||||
截至2021年12月31日的余额
|
5,304,452
|
280,310,744
|
30,591,209
|
(213,975,679
|
)
|
3,050,270
|
105,280,996
|
|
in €
|
2021
|
2020
|
2019
|
|||||||||
经营活动
|
||||||||||||
当期亏损
|
(45,630,059
|
)
|
(33,983,614
|
)
|
(53,254,817
|
)
|
||||||
对以下各项进行调整:
|
||||||||||||
财产和设备、使用权资产和无形资产的折旧和摊销
|
669,434
|
712,713
|
663,166
|
|||||||||
财务净收入
|
(2,004,757
|
)
|
40,810
|
(3,513,355
|
)
|
|||||||
基于股份的支付费用
|
4,332,205
|
1,116,791
|
6,832,210
|
|||||||||
净汇差
|
111,606
|
(247,322
|
)
|
(368,477
|
)
|
|||||||
其他非现金调整
|
—
|
3,436
|
60,628
|
|||||||||
以下内容中的更改:
|
||||||||||||
其他资产
|
(7,094,467
|
)
|
(1,554,611
|
)
|
(2,364,399
|
)
|
||||||
雇员福利
|
(3,290
|
)
|
355,545
|
235,500
|
||||||||
其他负债
|
19,863
|
8,960
|
(209,948
|
)
|
||||||||
收到的政府赠款的负债
|
8,300,000
|
—
|
—
|
|||||||||
贸易和其他应付款
|
316,112
|
(4,155,529
|
)
|
5,734,795
|
||||||||
收到的利息
|
1,070,235
|
1,201,547
|
3,001,109
|
|||||||||
支付的利息
|
(23,633
|
)
|
(26,387
|
)
|
(20,903
|
)
|
||||||
用于经营活动的现金净额
|
(39,936,750
|
)
|
(36,527,661
|
)
|
(43,204,492
|
)
|
||||||
投资活动
|
||||||||||||
购买无形资产和财产及设备
|
(37,778
|
)
|
(94,189
|
)
|
(594,889
|
)
|
||||||
购买非流动其他金融资产
|
—
|
—
|
(75,543
|
)
|
||||||||
购买流动和非流动金融资产
|
(97,516,417
|
)
|
(101,600,176
|
)
|
(82,547,409
|
)
|
||||||
流动金融资产到期收益
|
71,603,310
|
123,056,347
|
103,559,395
|
|||||||||
投资活动的现金净额
|
(25,950,885
|
)
|
21,361,982
|
20,341,554
|
||||||||
融资活动
|
||||||||||||
发行普通股所得款项
|
65,142,549
|
9,770,944
|
—
|
|||||||||
发行普通股的交易成本
|
(4,219,222
|
)
|
(729,841
|
)
|
—
|
|||||||
行使购股权所得款项
|
1,014,583
|
496,946
|
1,676
|
|||||||||
偿还租赁债务
|
(360,644
|
)
|
(366,156
|
)
|
(296,020
|
)
|
||||||
融资活动产生的现金净额[用于]
|
61,577,266
|
9,171,893
|
(294,344
|
)
|
||||||||
现金和现金等价物净增加/(减少)
|
(4,310,369
|
)
|
(5,993,786
|
)
|
(23,157,282
|
)
|
||||||
汇率变动对现金及现金等价物的影响
|
4,591,683
|
(1,168,813
|
)
|
902,321
|
||||||||
期初现金及现金等价物
|
25,968,681
|
33,131,280
|
55,386,240
|
|||||||||
期末现金及现金等价物
|
26,249,995
|
25,968,681
|
33,131,280
|
|
|